https://scholars.lib.ntu.edu.tw/handle/123456789/484107
標題: | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | 作者: | YU-YUN SHAO ZHONG-ZHE LIN Chen T.-J. CHIUN HSU Ying-Chun Shen CHIH-HUNG HSU ANN-LII CHENG |
公開日期: | 2011 | 卷: | 81 | 期: | 2 | 起(迄)頁: | 98-103 | 來源出版物: | Oncology | 摘要: | Objectives: We examined whether circulating endothelial progenitor (CEP) and circulating endothelial cell (CEC) levels had associations with the survival of patients who received antiangiogenic therapy for advanced hepatocellular carcinoma (HCC). Methods: Patients with advanced HCC were enrolled into a phase II trial evaluating a combination of sorafenib and metronomic chemotherapy with tegafur/uracil as first-line systemic therapy. CEPs and CECs were enumerated with six-color flow cytometry at baseline, 2 weeks, and 4 weeks after treatment and analyzed for their associations with treatment outcomes along with other clinicopathologic factors. Results: Forty patients were enrolled. Baseline CEP and CEC levels were not associated with tumor stages, α-fetoprotein levels, or macrovascular invasion. By univariate analysis, a high baseline CEP level was a significant predictor of poor progression-free survival (PFS) and overall survival (OS) (p = 0.02 and p = 0.004, respectively). The high baseline CEP level remained an independent, significant predictor of poor PFS [hazard ratio (HR) 1.953, p = 0.049] and OS (HR 2.512, p = 0.004) in multivariate analysis. On the other hand, the baseline or posttreatment CEC levels were not associated with PFS or OS. Conclusion: High baseline CEP levels were associated with poor survival in patients with advanced HCC receiving sorafenib-based antiangiogenic combination therapy. Copyright ? 2011 S. Karger AG. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053557082&doi=10.1159%2f000331684&partnerID=40&md5=9a669040400e1115a75fe7ff5729a6fa https://scholars.lib.ntu.edu.tw/handle/123456789/484107 |
ISSN: | 0030-2414 | DOI: | 10.1159/000331684 | SDG/關鍵字: | alpha fetoprotein; sorafenib; UFT; antiangiogenic therapy; article; cancer invasion; cancer staging; cancer survival; clinical article; endothelial progenitor cell; female; flow cytometry; human; liver cell carcinoma; male; overall survival; phase 2 clinical trial; predictive value; priority journal; progression free survival; treatment duration; treatment outcome; Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Endothelial Cells; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pyridines; Stem Cells |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。